AVEO Oncology and Astellas Pharma Inc. discontinued a phase II study of tivozanib in locally recurrent or metastatic triple-negative breast cancer due to insufficient enrollment.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
